Insider Cluster (2 insiders) ·Filed May 19, 2026

VRTX

VERTEX PHARMACEUTICALS INC / MA
NEUTRAL
Impact 2/10
Horizonimmediate Processed4mo ago
Insider cluster: 2 insiders, $629K total
Actionable Insight • Neutral

No actionable signal. The $629K in insider sales is immaterial for a $111B market cap company. Both insiders sold on the same day, likely due to a planned 10b5-1 or blackout window opening. No bearish read-through to the stock. Monitor next 8-K or earnings for pipeline updates on Vertex's cystic fibrosis and pain programs.

DirectionNeutral
Confidencehigh
Horizonimmediate
Final — all horizons settled through T+60d
VRTX ▲ +17.60% at T+60d
NEUTRAL call ✓ call won +17.60% · α vs SPY +12.87% · entry $430.05 → $505.75
Entry anchored
May 19, 2026
via day open
T+1d
+0.77%
call +0.77% · α +0.58%
$433.38
settled 5mo ago
T+5d
+4.10%
call +4.10% · α +2.30%
$447.70
settled 4mo ago
T+20d
+6.73%
call +6.73% · α +6.77%
$458.99
settled 4mo ago
T+60d
+17.60%
call +17.60% · α +12.87%
$505.75
settled 7w ago

Price Chart

Loading chart...

Executive Summary

Two EVP-level insiders at Vertex (CMO and Chief Scientific Officer) sold open-market shares on the same day for a combined $629K. While this is a cluster of C-suite sales, the dollar amount represents only ~0.0006% of the company's $111B market cap — well below any material threshold. The sales occurred on the same date, which is consistent with a blackout-window opening or routine 10b5-1 plan execution rather than coordinated bearish sentiment.

Key Financial Metrics

Direction
selling
Total Value
$628.9K
Insiders
2

Key Facts

  • CMO Carmen Bozic sold 1,354 shares for $614K on May 15, 2026 at $453.45
  • CSO Mark Bunnage sold 33 shares for $15K on May 15, 2026 at $453.45
  • Combined sales of $629K represent ~0.0006% of $110.8B market cap
  • Both sales occurred on the same day, suggesting common timing trigger (blackout window or 10b5-1 plan)
  • Vertex has 82% analyst buy rating and $110.8B market cap
  • Historical model performance on VRTX reports shows net negative alpha at T+20 (-3.69% avg), though prior reports were mostly neutral with no directional bets

Financial Impact

Insider sales of $629K total, negligible relative to $110.8B market cap

insider holdingsdilution

Risk Factors

  • Insider sales are routine for large-cap biopharma and not predictive here
  • Model historical performance on VRTX reports shows negative alpha at T+20, but this is based on neutral calls and does not inform this filing's analysis

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
82% bullish (39 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-VRTX-1779221136715
11 reports for VRTX
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for VRTX — sortable, filterable
TypeNow
Jul 7, 2026
12w ago
8-K
BULLISH ★ 7/10
$522.25 $522.81▲ +0.11%▼ −1.89%$506.74 (−2.97%)
Jul 7, 2026
12w ago
Insider Cluster
NEUTRAL ★ 2/10
$522.25 $522.81▲ +0.11%▼ −1.89%$506.74 (−2.97%)
Jul 6, 2026
12w ago
Insider Cluster
NEUTRAL ★ 2/10
$529.59 $526.73▼ −0.54%▼ −2.26%$506.74 (−4.31%)
Jun 3, 2026
17w ago
Insider Cluster
NEUTRAL ★ 2/10
$441.47 $541.69▲ +22.70%▲ +21.08%$506.74 (+14.79%)
May 19, 2026
19w ago
Insider Cluster
NEUTRAL ★ 2/10
$430.05 $505.75▲ +17.60%▲ +12.87%$506.74 (+17.83%)
Mar 11, 2026
29w ago
Insider Cluster
NEUTRAL ★ 3/10
$491.96 $428.34▼ −12.93%▼ −24.45%$506.74 (+3.01%)
Feb 25, 2026
31w ago
Insider Cluster
NEUTRAL ★ 4/10
$482.92 $430.44▼ −10.87%▼ −17.82%$506.74 (+4.93%)
Feb 25, 2026
31w ago
Insider Cluster
BEARISH ★ 6/10
$482.92 $430.44▲ +10.87%▲ +17.82%$506.74 (−4.93%)
Feb 25, 2026
31w ago
Insider Cluster
NEUTRAL ★ 3/10
$482.92 $430.44▼ −10.87%▼ −17.82%$506.74 (+4.93%)
Feb 25, 2026
31w ago
Insider Cluster
NEUTRAL ★ 4/10
$482.92 $430.44▼ −10.87%▼ −17.82%$506.74 (+4.93%)
Showing 10 of 11

US Market Status

Market Closed — Opens in 1h 20m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published May 19, 2026